Skip to main content

Home/ Health affairs/ Group items tagged Early

Rss Feed Group items tagged

pharmacybiz

Early Detection Of Cancer : New Campaign By NHS - 0 views

  •  
    NHS chief executive Amanda Pritchard today (March 1) announced a new campaign to promote early detection of cancer, when it is easier to treat. The campaign, which would run across TV, radio, and social media from Wednesday (March 2), is the first to focus on tackling the fear of cancer rather thanspecific symptoms. It is in line with the NHS Long Term Plan's commitment to increase cancer detection at an early stage by 2028. As per the NHS figures, the number of people getting checked for cancer increased by over half a million between December 2020 and December 2021. Speaking ahead of the launch, Pritchard, said: "We know that the prospect of a cancer diagnosis can be daunting for people and that is exactly why we are launching this potentially lifesaving campaign - we want to allay people's fear about cancer and encourage them to get checked without delay.
pharmacybiz

Alzheimer's :Sugar molecule in blood can predict - 0 views

  •  
    Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies. Researchers at Sweden's Karolinska Institutet have revealed that the level of tau, a protein that plays a vital role in the development of severe dementia, is associated with a kind of sugar molecule in the blood. The study, which is published in Alzheimer's & Dementia, can pave the way for a simple screening procedure able to predict onset ten years in advance. "The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research," says the study's first author Robin Zhou, medical student and affiliated researcher at the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet. "We demonstrate in our study that blood levels of glycans are altered early during the development of the disease. This could mean that we'll be able to predict the risk of Alzheimer's disease with only a blood test and a memory test." In Alzheimer's disease, the neurons of the brain die, which is thought to be a result of the abnormal accumulation of the proteins amyloid beta and tau. Clinical trials for Alzheimer's drugs show that treatment should commence early in the pathological process, before too many neurons have died, to reverse the process before it is too late.
pharmacybiz

Abemaciclib : NICE recommends for early breast cancer - 0 views

  •  
    The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."
pharmacybiz

Healthy Habits After Addiction : Unlock Your Recovery - 0 views

  •  
    The incredible consequences that drug misuse has imposed on humans in the last few years make it one of the most pressing issues facing such nations. A person who is addicted to drugs or alcohol often turns to these substances as a crutch while they're going through tough times. Taking the drug regularly becomes habitual since it provides short-term relief without permanently resolving the issue. An important part of becoming sober is learning to substitute better routines for the addict's old, harmful ones. These self-care routines and healthy habits are much better ways to deal with stress. Here we will explain how healthy behavior throughout addiction recovery is simply one of many methods to adapt to life after treatment. Physical Activity Scientific studies have shown that physical activity increases levels of two hormones. dopamine and serotonin, which are linked to better mood. A more positive outlook, restful sleep, and enhanced general health are all possible outcomes of these hormones. In the early stages of your rehabilitation, it is wise to start an exercise regimen that you have never done before. You may find new sober friends and interactions, as well as inspiration to improve your physical health, by connecting with other people who share your interests in physical activity. In the early stages of recovery, having sober friends may be really helpful since it allows you to connect with those who understand what you're going through. Friendships formed in early recovery often continue long after the addict has left the program, according to many people in recovery.
pharmacybiz

NHS Expands Revolutionary Lung Health Checks - 0 views

  •  
    The NHS England is rapidly expanding the targeted lung health check programme (TLHC) across England to detect lung cancers at an early stage. Launched in 2019, it is a national scheme that identifies people aged 55-74 at increased risk of lung cancer to invite them for a lung health check and chest CT scan, if appropriate. Since then, it has heled detect over 3,000 lung cancers, mostly at an early stage when the condition is more treatable, Dr Jason Page, Clinical Director of South Yorkshire and Bassetlaw targeted lung health checks, revealed in a blog on the NHS website. The decision to initiate the programme follows a study that showed CT screening reduced lung cancer mortality by 26 per cent in men and between 39 per cent and 61 per cent in women.
pharmacybiz

Pharmacy Leaders applaud Lib Dem election manifesto for sustainable healthcare reforms - 0 views

  •  
    Released on Monday morning, the election manifesto shared by the Liberal Democrats pledges to "strengthen patients' rights" by tackling public health inequalities and providing early access to community services. The Liberal Democrats Party's manifesto promises to address the issues at both the "front and back doors" of the National Health Service (NHS), which the party claims has been plunged into crisis by the Conservatives. Pledging to invest in public health and early access to community services, the party aims to "work towards a fairer and more sustainable long-term funding model for pharmacies and build on the Pharmacy First approach to give patients more accessible routine services and ease the pressure on GPs." The pledge also includes making prescriptions for people with chronic mental health conditions free on the NHS, as part of a wider commitment to review the entire schedule of exemptions for prescription charges.
healthcare_jobs

Merit Badges and Early Retirement | HospitalRecruiting.com - 0 views

  •  
    Administrative bureaucracy has a tendency to crush the spirit of those working on the front lines. This article serves as a lament from one physician on the notion of merit badges, and mandated recertifications. Read More: https://www.hospitalrecruiting.com/blog/7360/merit-badges-and-early-retirement/
pharmacybiz

British researchers start recruiting for clinical trial to test novel antiviral Covid-1... - 0 views

  •  
    Researchers from the University of Oxford today (December 8) started recruiting for a clinical trial to test novel antiviral Covid-19 treatments for early use in the illness by people in the community and those who are at higher risk of complications. Partnering with the National Institute for Health Research (NIHR), colleagues in several UK universities, and the NHS UK-wide, the Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC), is a national priority trial, and will be open to participants from across the UK. The first treatment to be tested by the UK Antiviral Taskforce will be molnupiravir, a Covid antiviral pill already licensed by the MHRA. Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.
pharmacybiz

NHS sets new record of three million cancer checks in 12 month - Latest Pharmacy News |... - 0 views

  •  
    NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than before the pandemic, revealed NHS. Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the pandemic. "Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every day over the last year," said NHS. In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests, mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease. More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of the biggest programme to improve early lung cancer diagnosis in health service history.
kailashdh

The Importance of Early Detection in Heart Valve Disease - 0 views

  •  
    Discover the significance of early detection in heart valve disease, the common types and symptoms, and introduce you to the importance of consulting the best cardiologist.
pharmacybiz

Experimental obesity drug has promising durability:Amgen - 0 views

  •  
    Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.
pharmacybiz

'Early signs' monkeypox outbreak plateauing in UK:UKHSA - 0 views

  •  
    The UK Health Security Agency (UKHSA) said last week (Aug 5) there were "early signs" that the monkeypox outbreak was plateauing across the country and that its expansion had slowed. "While the most recent data suggests the growth of the outbreak has slowed, we cannot be complacent," Dr Meera Chand, director of clinical and emerging infections at UKHSA, said. There were 2,859 confirmed and highly probable cases of monkeypox in the UK as of Aug. 4, with nearly 99 per cent of the cases among men, the country's health authority said in a statement. The recent analysis by the UKHSA showed that "monkeypox continues to be transmitted primarily in interconnected sexual networks of gay, bisexual, or other men who have sex with men", it added. British authorities in June were recommending gay and bisexual men at higher risk of exposure to monkeypox be offered a vaccine, as the outbreak of the viral disease had gathered pace, mostly in Europe.
pharmacybiz

Eli Lilly drug slows Alzheimer's by 35%:Company - 0 views

  •  
    An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.
pharmacybiz

RPS Unveils 3 Awards - Daniel Thomas,OPERA and Barnett - 0 views

  •  
    The Royal Pharmaceutical Society (RPS) announced three new awards - the Daniel Thomas Award, the OPERA Award and the Barnett Award - at its annual conference on Friday. RPS President Professor Claire Anderson said each award recognises "exceptional contributions to the pharmacy field." The Daniel Thomas Award recognises pharmacists or pharmaceutical scientists who died while actively practising in the profession. It is named after Daniel Thomas, a pharmacist who died during the First World War in 1917 while serving with the Royal Army Medical Corps. The Outstanding Pharmacy Early-Career Researcher Award or OPERA Award recognises the achievements of early-career researchers within the pharmacy field.
pharmacybiz

Consultation on draft standards for hospital chief pharmacists expected by early 2024,'... - 0 views

  •  
    Duncan Rudkin, the CEO of the General Pharmaceutical Council (GPhc) has highlighted the importance of strengthening pharmacy governance to provide clarity around how pharmacies are organised and managed. This will ensure that patients and the public continue to receive safe and effective pharmacy care, he said while speaking at the annual Sigma Conference in London on Sunday (5 November). According to him, there could be rules that outlined the essential roles and responsibilities of responsible pharmacists, and professional standards for responsible pharmacists, superintended pharmacists and chief pharmacists. He also announced that the GPhC will be shortly launching a consultation to integrate a new set of standards for the statutory role of hospital chief pharmacists "which up until recently has never been recognised in law." It is expected to be launched by early January 2024. However, Duncan, emphasised that they cannot start the work on standards for responsible and superintendent pharmacists until they know the government plans in relation to supervision. "Because of course, the responsible pharmacists' regime, and the supervision regime are in many ways intertwined, and can't certainly be looked at separately.
pharmacybiz

Fuller 'blueprint' backs community pharmacy - 0 views

  •  
    NHS England and NHS Improvement published on May 26 the findings of the Fuller 'stocktake' - setting out how primary care can work with partners across health and care to best meet the needs of their local communities. Dr Claire Fuller's report lays emphasis on the essential role of primary care and the potential of integrated neighbourhood teams in reducing the burden of ill health and tackling health inequities. It commends community pharmacy for keeping "its doors open to the public throughout" the pandemic whilst being "among the most recognisable of a multitude of dedicated staff delivering care around the clock in every neighbourhood in the country". The report highlights "recruitment and retention challenges across the wider primary care workforce" including in community pharmacy. Stressing the importance of community pharmacy teams in urgent care and prevention, including early diagnosis of cancers, the report points out that pharmacists could play "a more active role in signposting eligible people to screening and supporting early diagnosis, building on a number of successful pilots such as those from the Accelerate, Coordinate, Evaluate (ACE) programme".
pharmacybiz

Paxlovid : MHRA Approves Second Oral Covid-19 Antiviral - 0 views

  •  
    UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir. The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection. Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection. A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent. It further revealed that Paxlovid is most effective when taken in the early stage of infection. Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."
pharmacybiz

Innovative Medicines Fund : £340m NHS fund - 0 views

  •  
    The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available to purchase potentially life-saving drugs early. This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or save their lives. "The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people renewed hope for a better future." A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients. DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to the smaller patient cohort.
pharmacybiz

Eisai :Files for approval of Alzheimer's drug in Europe - 0 views

  •  
    Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.
pharmacybiz

Lung Cancer Patients To Benefit From New Drug On NHS - 0 views

  •  
    Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.
1 - 20 of 138 Next › Last »
Showing 20 items per page